Literature DB >> 21502568

Prevalence of resistant hypertension in the United States, 2003-2008.

Stephen D Persell1.   

Abstract

The prevalence of resistant hypertension is unknown. Much previous knowledge comes from referral populations or clinical trial participants. Using data from the National Health and Nutrition Examination Survey from 2003 through 2008, nonpregnant adults with hypertension were classified as resistant if their blood pressure was ≥140/90 mm Hg and they reported using antihypertensive medications from 3 different drug classes or drugs from ≥4 antihypertensive drug classes regardless of blood pressure. Among US adults with hypertension, 8.9% (SE: 0.6%) met criteria for resistant hypertension. This represented 12.8% (SE: 0.9%) of the antihypertensive drug-treated population. Of all drug-treated adults whose hypertension was uncontrolled, 72.4% (SE: 1.6%) were taking drugs from <3 classes. Compared with those with controlled hypertension using 1 to 3 medication classes, adults with resistant hypertension were more likely to be older, to be non-Hispanic black, and to have higher body mass index (all P<0.001). They were more likely to have albuminuria, reduced renal function, and self-reported medical histories of coronary heart disease, heart failure, stroke, and diabetes mellitus (P<0.001). Most (85.6% [SE: 2.4%]) individuals with resistant hypertension used a diuretic. Of this group, 64.4% (SE: 3.2%) used the relatively weak thiazide diuretic hydrochlorothiazide. Although not rare, resistant hypertension is currently found in only a modest proportion of the hypertensive population. Among those classified here as resistant, inadequate diuretic therapy may be a modifiable therapeutic target. Cardiovascular diseases, diabetes mellitus, obesity, and renal dysfunction were all common in this population.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21502568     DOI: 10.1161/HYPERTENSIONAHA.111.170308

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  241 in total

1.  Heart disease and stroke statistics--2012 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Elsayed Z Soliman; Paul D Sorlie; Nona Sotoodehnia; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2011-12-15       Impact factor: 29.690

2.  Incidence and prognosis of resistant hypertension in hypertensive patients.

Authors:  Stacie L Daugherty; J David Powers; David J Magid; Heather M Tavel; Frederick A Masoudi; Karen L Margolis; Patrick J O'Connor; Joe V Selby; P Michael Ho
Journal:  Circulation       Date:  2012-02-29       Impact factor: 29.690

3.  Use of enoximone in management of anaphylaxis complicated by labetalol use.

Authors:  Sophie Hayhoe; Vilas Navapurkar; Andrew Conway Morris
Journal:  BMJ Case Rep       Date:  2015-10-26

Review 4.  The rise, fall, and possible resurrection of renal denervation.

Authors:  Rajiv Gulati; Claire E Raphael; Manuela Negoita; Stuart J Pocock; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

5.  Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort.

Authors:  David A Calhoun; John N Booth; Suzanne Oparil; Marguerite R Irvin; Daichi Shimbo; Daniel T Lackland; George Howard; Monika M Safford; Paul Muntner
Journal:  Hypertension       Date:  2013-12-09       Impact factor: 10.190

Review 6.  Sodium-retaining effect of insulin in diabetes.

Authors:  Michael W Brands; M Marlina Manhiani
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-10-03       Impact factor: 3.619

7.  Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation.

Authors:  Jason D Foss; Gregory D Fink; John W Osborn
Journal:  Hypertension       Date:  2013-02-04       Impact factor: 10.190

Review 8.  Oh, the places you'll go! My many colored serotonin (apologies to Dr. Seuss).

Authors:  Stephanie W Watts
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-09-23       Impact factor: 4.733

Review 9.  Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension.

Authors:  Stefan C Bertog; Nathan A Sobotka; Paul A Sobotka; Melvin D Lobo; Kolja Sievert; Laura Vaskelyte; Horst Sievert; Roland E Schmieder
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

Review 10.  Apparent and true resistant hypertension: definition, prevalence and outcomes.

Authors:  E Judd; D A Calhoun
Journal:  J Hum Hypertens       Date:  2014-01-16       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.